Medreich PLC Pharmaceutical Import Profile — United Kingdom (DGFT 2022–2026)

Name: Medreich PLC Pharmaceutical Import Records from India — 11 Products, $28.9M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Medreich PLC — Pharmaceutical Importer Profile (2026) | 11 Products, $28.9M Trade | TransData Nexus

Medreich PLC

Pharmaceutical Importer · United Kingdom · Advanced Antibiotics Focus · $28.9M Total Trade · DGFT Verified

Medreich PLC is a pharmaceutical importer based in United Kingdom with a total trade value of $28.9M across 11 products in 8 therapeutic categories. Based on 893 verified import shipments from Indian Customs (DGFT) records, Medreich PLC is the #1 buyer in 1 product including Flucloxacillin. Medreich PLC sources from 2 verified Indian suppliers, with Medreich Limited accounting for 99.6% of imports.

Medreich PLC — Import Portfolio & Supplier Network

Medreich PLC import network — 11 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Medreich PLC?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Medreich Limited	$51.7M	2,114	99.6%
Zeiss Pharma Limited	$231.7K	12	0.4%

Medreich PLC sources from 2 verified Indian suppliers across 1,351 distinct formulations. The sourcing is highly concentrated — Medreich Limited accounts for 99.6% of total imports, indicating a strategic single-source relationship.

What Formulations Does Medreich PLC Import?

Formulation	Value	Ships
Phenoxymethyl penicillin potassium	$1.2M	28
Amoxicillin sugar free suspension	$1.1M	46
Fexofenadine hydrochloride tablets 180MG	$767.8K	16
Flucloxacillin 500MG capsules BP 2x14s	$569.8K	14
Gliclazide tablets BP 80MG 2x14s	$441.0K	10
Paracetamol 500MG+codeine 15MG	$413.6K	9
Flucloxacillin 500MG capsules BP	$406.8K	10
Nefopam hydrochloride 30MG film coated	$390.5K	11
Flucloxacillin capsules BP 500MG 2x14s	$374.7K	10
Paracetamol 500MG+codeine 15MG tablets	$338.7K	7
Metformin hcl 500MG prolonged release	$301.7K	14
Diclofenac sodium 50MG gastro	$255.6K	12
Gliclazide tablets BP 80MG 2x14s	$254.2K	6
Metformin hydrochloride 1000MG tablets	$210.1K	10
Metformin hydrochloride 500MG	$207.5K	8

Medreich PLC imports 1,351 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 11 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Flucloxacillin	Advanced Antibiotics	$7.8M	157	20.2%	1
2	Amoxicillin	Antibiotics	$6.4M	170	1.1%	11
3	Codeine	Analgesics & Antipyretics	$3.4M	68	3.1%	3
4	Gliclazide	Advanced Diabetes Medications	$3.1M	68	1.0%	7
5	Fluoxetine	CNS & Psychiatric	$2.2M	125	0.9%	11
6	Bisoprolol	Cardiovascular	$2.1M	137	2.5%	6
7	Fexofenadine	Antihistamines & Allergy	$1.6M	33	1.5%	13
8	Terbinafine	Antifungals	$838.7K	30	3.1%	7
9	Aspirin	Analgesics & Antipyretics	$641.7K	54	1.7%	11
10	Amiodarone	Cardiovascular	$371.1K	16	0.5%	16
11	Isosorbide	Cardiovascular	$314.3K	35	0.7%	14

Medreich PLC imports 11 pharmaceutical products across 8 categories into United Kingdom totaling $28.9M. The company is the #1 buyer for 1 product: Flucloxacillin.

Medreich PLC — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Medreich PLC is a public limited company incorporated in the United Kingdom on 7 November 1995, with its registered office at Warwick House, Plane Tree Crescent, Feltham, London, TW13 7HF. (find-and-update.company-information.service.gov.uk) The company operates as a pharmaceutical wholesaler, specializing in the importation and distribution of finished pharmaceutical formulations. Medreich PLC is a subsidiary of Medreich Limited, a fully integrated pharmaceutical company based in Bengaluru, India, established in 1973. Medreich Limited became part of Japan's Meiji Seika Pharma in 2015 and operates within the Meiji Group, which is listed on the Tokyo Stock Exchange.

In the United Kingdom, Medreich PLC plays a significant role in the pharmaceutical supply chain by importing and distributing a diverse range of finished pharmaceutical products. The company's operations are supported by a state-of-the-art packaging line and quality control testing laboratory in Feltham, London, along with warehousing facilities to cater to the expanding demand in the European region.

2Distribution Network

Medreich PLC's distribution network is strategically located to serve the United Kingdom and broader European markets. The company's primary warehouse and distribution center are situated at Warwick House, Plane Tree Crescent, Feltham, London, TW13 7HF. (find-and-update.company-information.service.gov.uk) This facility is equipped with advanced packaging lines and quality control testing laboratories, ensuring efficient handling and distribution of pharmaceutical products. The proximity to major transportation hubs facilitates timely delivery across the United Kingdom and to other European destinations.

3Industry Role

Medreich PLC functions as a pharmaceutical wholesaler in the United Kingdom, importing and distributing finished pharmaceutical formulations. The company holds a Wholesale Distribution Authorisation (WDA(H)) from the Medicines and Healthcare products Regulatory Agency (MHRA), which authorizes it to procure, hold, supply, and export medicinal products. (cms.mhra.gov.uk) Additionally, Medreich PLC possesses a Manufacturer's Authorisation (MIA) from the MHRA, permitting it to conduct manufacturing operations, including packaging and quality control testing of imported medicinal products. (cms.mhra.gov.uk)

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Medreich PLC

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Medreich PLC's sourcing strategy exhibits a high degree of concentration, with a significant majority of its pharmaceutical imports originating from a single supplier, Medreich Limited. Between 2022 and 2026, Medreich PLC imported finished pharmaceutical formulations valued at $28.9 million USD across 893 shipments, with Medreich Limited accounting for 99.6% of these imports. This concentration indicates a strategic choice to maintain a streamlined supply chain and leverage the established relationship with its parent company.

The stability of this sourcing relationship is further evidenced by the consistent volume of imports over the period, suggesting a reliable and efficient supply chain. However, the minimal involvement of other suppliers, such as Zeiss Pharma Limited, which contributed 0.4% of the imports, indicates limited diversification in sourcing. This lack of diversification could pose risks in the event of supply chain disruptions or changes in the supplier's operational capabilities.

2Supply Chain Resilience

Medreich PLC's supply chain resilience is closely tied to its sourcing strategy, which predominantly relies on Medreich Limited for pharmaceutical imports. The limited number of suppliers suggests a potential vulnerability to supply chain disruptions. The company's reliance on a single supplier may expose it to risks associated with production delays, quality control issues, or regulatory challenges faced by Medreich Limited.

Importing Pharmaceuticals into United Kingdom — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United Kingdom

1Regulatory Authority & Framework

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) serves as the primary regulatory authority overseeing the pharmaceutical sector. The MHRA is responsible for ensuring that medicines and medical devices meet appropriate standards of safety, quality, and efficacy. Key legislation governing pharmaceutical imports includes the Human Medicines Regulations 2012, which outline requirements for marketing authorizations, manufacturing authorizations, and wholesale distribution authorizations. (cms.mhra.gov.uk)

The MHRA's regulatory framework encompasses various aspects of pharmaceutical imports, including the need for a Marketing Authorisation (MA) for medicinal products, a Wholesale Distribution Authorisation (WDA(H)) for wholesalers, and compliance with Good Manufacturing Practice (GMP) standards. These regulations ensure that imported medicines are safe for use and meet the required quality standards. (gov.uk)

2Import Licensing & GMP

To import human medicines into the United Kingdom, companies must obtain specific licenses from the MHRA. A Wholesale Distribution Authorisation (WDA(H)) is required for the wholesale distribution of medicinal products, authorizing the holder to procure, hold, supply, and export medicines. Additionally, a Marketing Authorisation (MA) is necessary for each medicinal product, confirming that the product has been evaluated and approved for sale in the UK market. (gov.uk)

Medreich PLC — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Medreich PLC's product strategy focuses on importing and distributing a diverse range of finished pharmaceutical formulations across various therapeutic categories. Between 2022 and 2026, the company imported 11 products spanning eight therapeutic areas, with the top five products being Flucloxacillin, Amoxicillin, Codeine, Gliclazide, and Fluoxetine. This strategic selection indicates a focus on high-demand medications in the United Kingdom market.

The market demand for these products is driven by factors such as the prevalence of bacterial infections, the need for effective analgesics, and the management of chronic conditions like diabetes. By focusing on these therapeutic areas, Medreich PLC aims to address critical healthcare needs and maintain a competitive position in the pharmaceutical distribution sector.

2Sourcing Profile

Medreich PLC's sourcing strategy is predominantly centered on importing finished pharmaceutical formulations from Medreich Limited, its parent company in India. This approach leverages the established manufacturing capabilities and regulatory compliance of Medreich Limited, ensuring a consistent supply of quality products. The company's focus on finished formulations aligns with its role as a wholesaler and distributor in the United Kingdom, catering to the needs of healthcare providers and patients.

India's robust pharmaceutical manufacturing sector, characterized by compliance with international standards and a diverse product portfolio

Frequently Asked Questions — Medreich PLC

What products does Medreich PLC import from India?

Medreich PLC imports 11 pharmaceutical products across 8 categories. Top imports: Flucloxacillin ($7.8M), Amoxicillin ($6.4M), Codeine ($3.4M), Gliclazide ($3.1M), Fluoxetine ($2.2M).

Who supplies pharmaceuticals to Medreich PLC from India?

Medreich PLC sources from 2 verified Indian suppliers. The primary supplier is Medreich Limited (99.6% of imports, $51.7M).

What is Medreich PLC's total pharmaceutical import value?

Medreich PLC's total pharmaceutical import value from India is $28.9M, based on 893 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Medreich PLC focus on?

Medreich PLC imports across 8 categories. The largest: Advanced Antibiotics (27.1%), Antibiotics (22.2%), Analgesics & Antipyretics (14.0%).

Get Full Medreich PLC Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.